Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL - report from ASH 2025

from Medical Digest & Congress Report · host Medical Congress News

Jennifer Woyach discusses the noncovalent BTK inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with CLL or SLL, according to findings from a randomized phase III trial presented at the American Society of Hematology's 67th Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:non-covalent-btki-pirtobrutinib-shows-promise-frontline-therapy-cllsll

Episode metadata supplied by the publisher feed · Published Jan 7, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL - report from ASH 2025

0:00 6:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on January 7, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!